Invivyd Stock Today
| IVVD Stock | USD 1.74 0.11 5.95% |
PerformanceMild
| Odds Of DistressHigh
|
Invivyd is trading at 1.74 as of the 3rd of February 2026, a 5.95% down since the beginning of the trading day. The stock's lowest day price was 1.74. Invivyd has more than 62 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 5th of November 2025 and ending today, the 3rd of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of August 2021 | Category Healthcare | Classification Health Care |
Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Invivyd, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts. The company has 281.99 M outstanding shares of which 21.41 M shares are currently shorted by private and institutional investors with about 4.75 trading days to cover. More on Invivyd
Moving against Invivyd Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Invivyd Stock Highlights
| VP CEO | Heidi MS | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsBy employing borrowed capital, Invivyd can potentially magnify investment returns. Examining the debt-to-assets ratio offers investors perspective on Invivyd's use of financial leverage and reveals what portion of Invivyd's asset base relies on creditor financing.
| |||||
Invivyd (IVVD) is traded on NASDAQ Exchange in USA and employs 99 people. Invivyd is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 490.66 M. Invivyd conducts business under Biotechnology sector and is part of Health Care industry. The entity has 281.99 M outstanding shares of which 21.41 M shares are currently shorted by private and institutional investors with about 4.75 trading days to cover.
Invivyd currently holds about 418.67 M in cash with (170.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Invivyd Probability Of Bankruptcy
Ownership AllocationInvivyd has a total of 281.99 Million outstanding shares. The majority of Invivyd outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Invivyd to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Invivyd. Please pay attention to any change in the institutional holdings of Invivyd as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Invivyd Ownership Details
Invivyd Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2025-06-30 | 637 K | |
| Deutsche Bank Ag | 2025-06-30 | 585.4 K | |
| Morgan Stanley - Brokerage Accounts | 2025-06-30 | 513.4 K | |
| Gsa Capital Partners Llp | 2025-06-30 | 435.3 K | |
| Aqr Capital Management Llc | 2025-06-30 | 423.5 K | |
| Tang Capital Management Llc | 2025-06-30 | 400 K | |
| Goldman Sachs Group Inc | 2025-06-30 | 387.9 K | |
| Cubist Systematic Strategies, Llc | 2025-06-30 | 326.8 K | |
| State Street Corp | 2025-06-30 | 272.9 K | |
| Mithril Ii Gp Lp | 2025-06-30 | 11.2 M | |
| Maverick Capital Ltd | 2025-06-30 | 10.2 M |
Invivyd Historical Income Statement
Invivyd Stock Against Markets
Invivyd Corporate Management
| Laura Walker | CoFounder Officer | Profile | |
| Elham PharmD | Chief Officer | Profile | |
| Peter MD | Chief Officer | Profile | |
| Robert Allen | Chief Officer | Profile | |
| Jill JD | Chief Secretary | Profile | |
| Mark Wingertzahn | Senior Affairs | Profile | |
| Timothy Lee | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Invivyd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Invivyd Stock refer to our How to Trade Invivyd Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Will Biotechnology sector continue expanding? Could Invivyd diversify its offerings? Factors like these will boost the valuation of Invivyd. Market participants price Invivyd higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Invivyd data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.45) | Revenue Per Share | Quarterly Revenue Growth 0.412 | Return On Assets | Return On Equity |
Understanding Invivyd requires distinguishing between market price and book value, where the latter reflects Invivyd's accounting equity. The concept of intrinsic value—what Invivyd's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Invivyd's price substantially above or below its fundamental value.
Please note, there is a significant difference between Invivyd's value and its price as these two are different measures arrived at by different means. Investors typically determine if Invivyd is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Invivyd's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.